effect of supplement containing Astaxanthin and alpha linolenic acid in coronary artery stenosis

A clinical trial to compare the effect of supplement containing Astaxanthin and alpha linolenic acid with placebo on serum levels of leptin and adiponectin, hs-CRP, miocardio vascular adhesion factors, nitric oxide and lipid profile in patients with mild to moderate coronary artery stenosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016050327727N1

Enrollment

Registered

2017-02-09

Start date

2016-06-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease. Atherosclerotic heart disease

Interventions

Intervention 1: Intervention group: in this group, one oral supplement tablet containing 4 mg of Astaxanthin and 300mg alpha-Linolenic acid, produced in USA is prescribed. It should be used daily for

Treatment - Drugs

Placebo

Intervention group: in this group, one oral supplement tablet containing 4 mg of Astaxanthin and 300mg alpha-Linolenic acid, produced in USA is prescribed. It should be used daily for 8 weeks

Control group: in this group, a placebo pill produced in the form of oil capsule by Barij Company containing paraffin, is prescribed. It should be used daily for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Willingness to participate in the study; age range over 18 years; Patients who are suffering from ischemic heart disease with 30 -70 percent stenosis and are not candidates for coronary angioplasty. Exclusion criteria: having chronic disease; Blood or immunologic disorders; Hypothyroidism; Cardiogenic shock; Myocardial infarction with elevation of ST-segment; Pregnant and lactating women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Adiponectin. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;Leptin. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;Vascular cell adhesion molecule 1. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;E-selectin. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;C-reactive protein. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;Nitric Oxide. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;Malondialdehyde. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;High-density lipoprotein. Timepoint: Befor intervention and two months after intervention. Method of measurement: spectrophotometer Test.;Low-density lipoprotein. Timepoint: Befor intervention and two months after intervention. Method of measurement: spectrophotometer Test.;Triglycerides. Timepoint: Befor intervention and two months after intervention. Method of measurement: spectrophotometer Test.;Total cholesterol. Timepoint: Befor intervention and two months after intervention. Method of measurement: spectrophotometer Test.	—

Measure

Time frame

Adiponectin. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;Leptin. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;Vascular cell adhesion molecule 1. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;E-selectin. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;C-reactive protein. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;Nitric Oxide. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;Malondialdehyde. Timepoint: Befor intervention and two months after intervention. Method of measurement: ELISA Test.;High-density lipoprotein. Timepoint: Befor intervention and two months after intervention. Method of measurement: spectrophotometer Test.;Low-density lipoprotein. Timepoint: Befor intervention and two months after intervention. Method of measurement: spectrophotometer Test.;Triglycerides. Timepoint: Befor intervention and two months after intervention. Method of measurement: spectrophotometer Test.;Total cholesterol. Timepoint: Befor intervention and two months after intervention. Method of measurement: spectrophotometer Test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElmira yousefi

Ahvaz Jundishapour University of Medical Sciences

yousefi.e@ajums.ac.ir; eyousefi41@yahoo.com+98 61 3373 8330

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026